Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

Abstract: All cryo-CMOS quantum-classical control interfaces require an analog-to-digital converter (ADC) bridging the analog qubits and the digital control logic. Dynamic comparators play a crucial ...

Vein recognition technology offers high security and privacy as an advanced biometric identification method. While deep learning techniques have achieved state-of-the-art performance in vein ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

Code Vein getting a sequel, as announced at Summer Game Fest earlier this year, was a pleasant surprise. The original was good! It was one of those games that necessarily didn’t blow people away, but ...

There’s something comforting about a well-done workplace comedy. It’s the relatability of people sanded down by capitalism, forced to go into cubicles or other office spaces like so many viewers do ...

Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both fibrosis and the immune system. It will be available in the next few weeks. The ...

October 9, 2025—IceCure Medical Ltd. announced that the FDA has granted marketing authorization for its ProSense cryoablation system for the local treatment of early-stage, biologically low-risk ...